Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms, Second Primary 1Heart Failure 1Cardiotoxicity 1Breast Neoplasms 1Breast Diseases 1

Interventions

Letrozole 23Docetaxel 17Cyclophosphamide 13Zoledronic Acid 12Trastuzumab 12Anastrozole 12exemestane 11Tamoxifen 11Paclitaxel 11Capecitabine 10Fulvestrant 8Epirubicin 8pegfilgrastim 7Saline Solution 7Bupivacaine 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Sodium Chloride 6Filgrastim 6Carboplatin 6pegylated granulocyte colony-stimulating factor 5palbociclib 5Ropivacaine 5Dexmedetomidine 5Bevacizumab 5ribociclib 4eribulin 4Vinorelbine 4Tranexamic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × sacubitril and valsartan sodium hydrate drug combination × Breast × Clear all
NCT05465031 2025-03-14

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Silesian Centre for Heart Diseases

Phase 4 Recruiting
600 enrolled
Breast

Breast Diseases, Breast Neoplasms, Heart Failure, Neoplasms, Second Primary, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡